Absolute Return Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Absolute Return Capital’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-13,457	Closed	-$393K	–	1048
2014 Q2	$393K	Buy	13,457 +3,208	+31%	+$77.6K	﹤0.01%	884
2014 Q1	$265K	Buy	+10,249	New	+$274K	﹤0.01%	991

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Absolute Return Capital's PTLA Position: Q3 2014 in Review

Absolute Return Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2014, closing a stake of 13,457 shares — an estimated $393K sold.

Absolute Return Capital first reported a position in PTLA in Q1 2014 and held it in 2 quarters. The position peaked at $393K in Q2 2014. 108 funds tracked by Wall St. Rank hold PTLA as of Q3 2014.

Absolute Return Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
Absolute Return Capital sold 13,457 Portola Pharmaceuticals, Inc. shares in Q3 2014, an estimated $393K.
Absolute Return Capital first reported a position in Portola Pharmaceuticals, Inc. in Q1 2014 and held it in 2 quarters.
Absolute Return Capital's Portola Pharmaceuticals, Inc. position peaked at $393K in Q2 2014.
108 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.